Full Vaccine Value Assessment (FVVA) for a TCV-MAP, including the development of ‘best practice’ methodologies

For MAPs, the VIPS vision and five-year goal are: - Vision: To implement MAP products for priority vaccines to overcome country immunisation barriers to ensure equitable access to, and improved effectiveness of, vaccines in LMICs and contribute to global health security. - Goal of the VIPS five-year action plan for MAPs: To accelerate development and future country uptake of MAPs as a platform technology for vaccine delivery in LMICs.

The action plan has identified the development and communication of at least two value assessments for vaccine-MAPs as a critical enabler to inform and incentivise decision- making of key stakeholders.

A significant bottleneck in the ability to advance product development of vaccine MAPs is the requirement for investment in establishing a manufacturing facility. This can be best rationalised through a vaccine-MAP portfolio approach.

This first FVVA for TCV-MAP may inform the Wellcome Trust and other funders’ future investments in this candidate and the MAP platform more widely.

If favorable, it could accelerate TCV-MAP development and preparation for uptake; if not, the resources could be diverted to other, potentially more worthy innovations.

In addition, the methodologies developed during this FVVA test case may be applied to other vaccine MAPs or other vaccine product innovations.